Biogen (BIIB) PT Raised to $403 at BMO Capital on 4Q Report; '2018 Guidance Above Street With Room to Grow'
Tweet Send to a Friend
BMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $403.00 (from $394.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
